| Bioactivity | Pacmilimab (CX-072) is a potent PD-L1 inhibitor. Pacmilimab shows antitumor activity[1]. |
| In Vivo | Pacmilimab 在携带 MC38 肿瘤的小鼠中诱导的抗肿瘤反应与相同剂量的亲本抗体相当[1]。Pacmilimab 在小鼠 PD-L1 表达肿瘤中积累，外周非癌性淋巴组织摄取最少，这与在非肿瘤 PD-L1 表达组织中摄取有限和自身免疫保护相一致[1] . |
| Name | Pacmilimab |
| CAS | 2145091-51-4 |
| Storage | Please store the product under the recommended conditions in the Certificate of Analysis. |
| Reference | [1]. Naing A, et al. CX-072 (pacmilimab), a Probody ® PD-L1 inhibitor, in advanced or recurrent solid tumors (PROCLAIM-CX-072): an open-label dose-finding and first-in-human study. J Immunother Cancer. 2021 Jul;9(7):e002447. |